Tirilazad
Clinical data
Other names(8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one
ATC code
Identifiers
  • (16α)-21-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]-16-methylpregna-1,4,9(11)-triene-3,20-dione
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC38H52N6O2
Molar mass624.874 g·mol−1
3D model (JSmol)
  • O=C(CN4CCN(c2nc(nc(N1CCCC1)c2)N3CCCC3)CC4)[C@H]6[C@H](C)C[C@H]5[C@H]8C(=C/C[C@@]56C)\[C@]/7(/C=C\C(=O)\C=C\7CC8)C
  • InChI=1S/C38H52N6O2/c1-26-22-31-29-9-8-27-23-28(45)10-12-37(27,2)30(29)11-13-38(31,3)35(26)32(46)25-41-18-20-43(21-19-41)34-24-33(42-14-4-5-15-42)39-36(40-34)44-16-6-7-17-44/h10-12,23-24,26,29,31,35H,4-9,13-22,25H2,1-3H3/t26-,29-,31+,35-,37+,38+/m1/s1 checkY
  • Key:RBKASMJPSJDQKY-RBFSKHHSSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.[1]

References

  1. ^ Bath PM, Iddenden R, Bath FJ, Orgogozo JM, et al. (Tirilazad International Steering Committee) (2001). "Tirilazad for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (4): CD002087. doi:10.1002/14651858.CD002087. PMID 11687138.
Categories